275 related articles for article (PubMed ID: 15802001)
21. The role of high-density lipoprotein cholesterol in atherothrombosis.
Choi BG; Vilahur G; Viles-Gonzalez JF; Badimon JJ
Mt Sinai J Med; 2006 Jul; 73(4):690-701. PubMed ID: 16878275
[TBL] [Abstract][Full Text] [Related]
22. High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies.
Toth PP
Am J Cardiol; 2005 Nov; 96(9A):50K-58K; discussion 34K-35K. PubMed ID: 16291015
[TBL] [Abstract][Full Text] [Related]
23. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL
Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645
[TBL] [Abstract][Full Text] [Related]
24. High-density lipoprotein cholesterol and coronary heart disease.
Young CE; Karas RH; Kuvin JT
Cardiol Rev; 2004; 12(2):107-19. PubMed ID: 14766026
[TBL] [Abstract][Full Text] [Related]
25. Cholesterol and coronary events. The current thinking.
Jones PH
Postgrad Med; 2003 Apr; 113(4 Suppl):5-14. PubMed ID: 19667618
[TBL] [Abstract][Full Text] [Related]
26. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
Fazio S
Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
[TBL] [Abstract][Full Text] [Related]
27. [High density lipoproteins (HDL). A therapeutic objective in the atherosclerosis prevention?].
Pérez-Méndez O
Arch Cardiol Mex; 2004; 74(1):53-67. PubMed ID: 15125268
[TBL] [Abstract][Full Text] [Related]
28. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
Alagona P
Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805
[TBL] [Abstract][Full Text] [Related]
29. Statins and LDL-cholesterol lowering: an overview.
Stroes E
Curr Med Res Opin; 2005; 21 Suppl 6():S9-16. PubMed ID: 16138936
[TBL] [Abstract][Full Text] [Related]
30. Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy.
Rosenson RS
Am Heart J; 2006 Mar; 151(3):556-63. PubMed ID: 16504615
[TBL] [Abstract][Full Text] [Related]
31. Role of fibrates in reducing coronary risk: a UK Consensus.
UK HDL-C Consensus Group
Curr Med Res Opin; 2004; 20(2):241-7. PubMed ID: 15006019
[TBL] [Abstract][Full Text] [Related]
32. Is there evidence-based hypolipidemic treatment with clinical benefit beyond statins?
Goumas GS
Angiology; 2009; 60(1):93-8. PubMed ID: 19019838
[TBL] [Abstract][Full Text] [Related]
33. [The role of the high-density lipoprotein (HDL) particle in atherogenesis and potential methods to increase HDL concentrations].
Birjmohun RS; van der Steeg WA; Stroes ES; Kastelein JJ
Ned Tijdschr Geneeskd; 2006 Oct; 150(41):2245-50. PubMed ID: 17076358
[TBL] [Abstract][Full Text] [Related]
34. A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease.
Packard C
Atheroscler Suppl; 2006 Apr; 7(1):21-9. PubMed ID: 16504600
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease.
Shah PK
Eur Heart J; 2007 Jan; 28(1):5-12. PubMed ID: 17121756
[TBL] [Abstract][Full Text] [Related]
36. High density lipoprotein: guardian of the vascular system?
Packard C; Nunn A; Hobbs R;
Int J Clin Pract; 2002 Dec; 56(10):761-71. PubMed ID: 12510950
[TBL] [Abstract][Full Text] [Related]
37. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
Meas T; Laloi-Michelin M; Virally M; Peynet J; Giraudeaux V; Kévorkian JP; Guillausseau PJ
Eur J Intern Med; 2009 Mar; 20(2):197-200. PubMed ID: 19327612
[TBL] [Abstract][Full Text] [Related]
38. HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?
März W; Köenig W
J Cardiovasc Risk; 2003 Jun; 10(3):169-79. PubMed ID: 12775949
[TBL] [Abstract][Full Text] [Related]
39. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
40. Lipid-altering therapies and the progression of atherosclerotic disease.
Wierzbicki AS
Cardiovasc Intervent Radiol; 2007; 30(2):155-60. PubMed ID: 17206389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
